TMDX logo

TRANSMEDICS GROUP INC

TMDXNASDAQ
🏆 #1714 by market capUS Equity
$173.34▲ $12.97 (+7.48%)
Simulated price
🔔
Track TMDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.95B
Small Cap
📈Revenue Growth (YoY)
+37.1%
High Growth
📊Gross Margin
58.7%
Healthy
💵FCF Margin
11.8%
Healthy
⚖️P/S Ratio
4.4x
Fair
Otter Score
56
Weak
No chart data available for TMDX.

Trading Snapshot

Day Range
$171.58 – $175.56
52-Week Range
$60.11 – $156.00
Volume
$1.93B
Avg Volume
$2.27B
Shares Outstanding
34.6M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$605M
Last Q Revenue
$190M
P/E Ratio
19.3
P/S Ratio
4.4x
EPS (TTM)
$4.39
Dividend Yield
0.00%
Dilution (1yr)
+16.2%

Why Investors Own TMDX

  • ✓High-growth profile — revenue up +4.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TMDX logo

TRANSMEDICS GROUP INC

TMDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$605M▲ +37.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.9%▲ +0.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$109M▲ +189.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$134M▼ −265.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.9M▲ +16.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19M▲ +$200M YoY
StockOtter · stockotter.space

About TRANSMEDICS GROUP INC

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$195.43
▲ +12.7% Upside
High Target$241.40
Low Target$144.87
Based on 35 analysts

Latest News & Updates

🚀
CNBC·2h ago

TRANSMEDICS GROUP INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TMDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

TRANSMEDICS GROUP INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.